Stryker Corporation $SYK Shares Bought by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 83.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,526 shares of the medical technology company’s stock after purchasing an additional 11,598 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Stryker were worth $8,037,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker during the 2nd quarter valued at $205,000. Marshall Wace LLP grew its stake in shares of Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new stake in Stryker in the second quarter worth $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker in the 2nd quarter valued at approximately $253,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $331.75 on Tuesday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s 50-day moving average is $325.21 and its 200-day moving average is $333.24. The firm has a market cap of $127.25 billion, a price-to-earnings ratio of 34.38, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SYK shares. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research report on Friday, May 1st. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Royal Bank Of Canada reduced their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Finally, Citigroup reissued a “buy” rating on shares of Stryker in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.